CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells Article

sustainable development goals

publication date

  • January 1, 2024

webpage

published in

keywords

  • ADC
  • CEACAM5
  • CEACAM6
  • SN-38
  • antibody-drug conjugate
  • pancreatic ductal adenocarcinoma

start page

  • 720

end page

  • 732

volume

  • 24

issue

  • 7